

The First Total Synthesis of the Antimicrobial Sesquiterpenes (\pm)-Enokipodins A and B

A. Srikrishna,* M. Srinivasa Rao

Department of Organic Chemistry, Indian Institute of Science, Bangalore 560012, India

E-mail: ask@orgchem.iisc.ernet.in

Received 15 October 2003

Abstract: Efficient first total synthesis of antimicrobial sesquiterpenes enokipodins A and B (**1** and **2**, respectively) and formal total synthesis of cuparene-1,4-diol (**5**) and cuparene-1,4-quinone (**7**) have been accomplished starting from 2,5-dimethoxy-4-methylacetophenone employing Claisen rearrangement and ring-closing metathesis reaction as key steps.

Key words: sesquiterpenes, enokipodins A and B, ring-closing metathesis, Claisen rearrangement

Flammulina velutipes (Curt.: Fr.) Sing. (Enokitake in Japanese) is a fresh edible mushroom frequently consumed in Japan. The natural compounds isolated (proteins, polysaccharides, glycolproteins, etc.) from the body of *F. velutipes* are known to have potent antitumor and immunomodulatory activities.¹ Recently, Takahashi and co-workers have reported² the bioassay guided isolation of four new sesquiterpenes enokipodins A–D (**1–4**) (Figure 1) from the mycelial culture medium of *F. velutipes*. Enokipodins A–D (**1–4**) exhibited significant antimicrobial activity against a fungus *Cladosporium herbarum*, and Gram-positive bacteria *Staphylococcus aureus* and *Bacillus subtilis*. Structurally, enokipodins A–D (**1–4**) are related to the less oxidised sesquiterpenes cuparene-1,4-diol (**5**) isolated³ from the Japanese liverwort *Lejeunea aquatica*, HM-1 **6** isolated⁴ from phytopathogenic fungus *Helicobasidium mompa* and the cuparene-1,4-quinone **7** (Figure 1) isolated⁵ from the liverwort *Radula javanica*, and more oxidised pigments lagopodins and helicobasidins.⁶ The cuparenoid sesquiterpenes pose significant challenge because of the difficulty associated in the generation of two adjacent quaternary carbon atoms in a cyclopentane ring and the regiochemical incorporation of polysubstituted aromatic ring. Despite the reported significant microbial activity, there is no report on the synthesis of enokipodins **1–4**. Very recently, Mukherjee and co-workers reported the first total synthesis of HM-1 methyl ether, cuparene-1,4-diol (**5**) and cuparene-1,4-quinone (**7**).⁷ The interesting biological properties associated with the enokipodins prompted us to develop a methodology for the synthesis of these sesquiterpenes. Herein, we report the first total synthesis of (\pm)-enokipodins A and B (**1** and **2**, respectively) along with a formal total synthesis of cuparene-1,4-diol (**5**) and cuparene-1,4-quinone (**7**).





Figure 1




Scheme 1

As the enokipodin A (**1**) is a hemiketal, the cyclopentanone **8** was identified as an ideal precursor for the generation of the enokipodins A and B (**1** and **2**, respectively) as well cuparenediol **5** and quinone **7** (Scheme 1). A combination of Claisen rearrangement and ring closing metathesis (RCM)⁸ reaction based strategy was envisaged for the synthesis of **8** starting from 2,5-dimethoxy-4-methylacetophenone (**9**) (readily available by Friedel–Crafts acylation of 2,5-dimethoxytoluene)⁹ via the cinnamyl alcohol **10** and the dienol **11**. The synthetic sequence is depicted in Scheme 2. Thus, Horner–Wadsworth–Emmons reaction of the acetophenone **9** with triethyl phosphonoacetate and NaH generated the cinnamate **12**, which on regioselective reduction with LiAlH₄ in Et₂O at low temperature furnished the allyl alcohol **10**. A one-pot Claisen rearrangement¹⁰ of the allyl alcohol **10** with ethyl vinyl

ether in the presence of mercuric acetate in a sealed tube at 175 °C furnished γ,δ -unsaturated aldehyde **13**. Alternatively, the aldehyde **13** was also prepared via the Johnson's orthoester variant of Claisen rearrangement of the cinnamyl alcohol **10** employing triethyl orthoacetate and propionic acid in a sealed tube at 180 °C followed by conversion of the resultant ester into the aldehyde **13** by LiAlH_4 reduction and PCC oxidation strategy. Grignard reaction of the aldehyde **13** with vinylmagnesium bromide furnished a 1:1 diastereomeric mixture of the key intermediate dienol **11**. RCM reaction of the diastereomeric mixture of the dienol **11** with 5 mol% of Grubbs' first generation catalyst furnished a 1:1 diastereomeric mixture of the cyclopentenol **14** in near quantitative yield, which on oxidation with pyridinium chlorochromate (PCC) and NaOAc generated the cyclopentenone **15**. One-step dialkylation of the enone **15** with NaH and MeI created the second quaternary carbon and generated the enone **16**, which on hydrogenation with 5% palladium over carbon as the catalyst at one atmosphere pressure of hydrogen (balloon) furnished the cyclopentanone **8**. Finally, demethylation of **8** with BBr_3 furnished directly the enokipodin **A 1** (mp 135–136 °C; lit.² 138.5–138.9 °C). On the other

hand, direct oxidation of the dimethyl ether **8** with ceric ammonium nitrate (CAN) in aqueous MeCN furnished enokipodin B **2** in a near quantitative yield. Huang–Minlon modified Wolff–Kishner reduction of the cyclopentanone **8** with hydrazine hydrate KOH in digol furnished the HM-1 methyl ether **17**, whose conversion to cuparene-1,4-diol (**5**) and cuparene-1,4-quinone (**7**) has already been reported.⁷ The synthetic enokipodins A and B have exhibited spectral data (IR, ^1H and ^{13}C NMR and mass) identical to those of natural products.²

In conclusion, we have developed the first total synthesis of (±)-enokipodins A and B employing a combination of Claisen rearrangement and RCM reactions as key steps. Starting from the readily available acetophenone **9**, enokipodin A and enokipodin B were obtained in 9 steps in 20.0% and 24.4% overall yields, respectively. In addition, a formal total synthesis of cuparene-1,4-diol (**5**) and cuparene-1,4-quinone (**7**) has also been accomplished. Currently, we are investigating the synthesis of optically active enokipodins and their higher oxidised analogues logopodins and helicobasidins for evaluating their biological potential.



Scheme 2 Reagents, conditions and yields: (a) $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{COOEt}$, NaH, THF, reflux, 5 h, 88%; (b) LiAlH_4 , Et_2O , -70°C to r.t., 2 h, 91%; (c) $\text{CH}_2=\text{CHOEt}$, $\text{Hg}(\text{OAc})_2$, sealed tube, 100 °C, 10 h; 175 °C, 48 h, 63%; (d) i. $\text{CH}_3\text{C}(\text{OEt})_3$, EtCOOH , sealed tube, 180 °C, 48 h, 70%; ii. LAH, Et_2O , -40°C to r.t., 2 h, 92%; iii. PCC-silica gel, CH_2Cl_2 , r.t., 1 h, 87%; (e) $\text{CH}_2=\text{CHMgBr}$, THF, r.t., 1 h, 88%; (f) 5 mol% $\text{PhCH}=\text{Ru}(\text{Cl})_2(\text{PCy}_3)_2$, CH_2Cl_2 , r.t., 4 h, 95%; (g) PCC, NaOAc, CH_2Cl_2 , r.t., 1 h, 86%; (h) NaH, THF–DMF, MeI, r.t., 12 h, 77%; (i) H_2 , 5% Pd/C, EtOH, 1 h, 92%; (j) BBr_3 , CH_2Cl_2 , 0 °C to r.t., 4 h, 78%; (k) CAN, $\text{CH}_3\text{CN}-\text{H}_2\text{O}$, r.t., 1 h, 95%; (l) $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$, digol, 120 °C, 3 h; KOH, digol, 190 °C, 12 h, 75%; (m) ref.⁷

Yields refer to isolated and chromatographically pure compounds. All compounds exhibited spectral data (IR, ^1H and ^{13}C NMR and Mass) consistent with the structures. Selected spectral data for the enone **15**: IR (neat): 1714 cm^{-1} . ^1H NMR (300 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 7.70 (d, J = 6.9 Hz, 1 H, H-3), 6.63 (s, 1 H, Ar-H), 6.56 (s, 1 H, Ar-H), 6.09 (d, J = 6.9 Hz, 1 H, H-2), 3.75 (s, 3 H, OCH_3), 3.73 (s, 3 H, OCH_3), 2.70, 2.50 (AB q, J = 18.6 Hz, 2 H, CH_2CO), 2.15 (s, 3 H, Ar- CH_3), 1.54 (s, 3 H, *tert*- CH_3). ^{13}C NMR (75 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 208.7 (C, C=O), 169.8 (CH, C-3), 151.3 (C), 151.1 (C), 131.3 (CH, C-2), 131.0 (C), 125.8 (C), 114.8 (CH, C-6'), 109.6 (CH, C-3'), 55.9 (CH₃, OCH_3), 55.5 (CH₃, OCH_3), 50.3 (CH₂, C-5), 47.1 (C, C-4), 27.6 (CH₃, *tert*- CH_3), 16.1 (CH₃, Ar- CH_3). MS: m/z (%) = 246 (96) [M^+], 231 (100), 216 (16), 203 (15), 188 (14), 173 (15), 128 (12), 115 (19), 91 (18). HRMS: m/z [$\text{M} + 1$] calcd for $\text{C}_{15}\text{H}_{19}\text{O}_3$: 247.1334; found: 247.1337. For the enone **16**: IR (neat): 1707, 1600, 1505, 1393, 1375, 1213, 1044, 861, 834, 789 cm^{-1} . ^1H NMR (300 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 7.84 (d, J = 6.0 Hz, 1 H, H-3), 6.66 (s, 1 H, Ar-H), 6.45 (s, 1 H, Ar-H), 6.10 (d, J = 6.0 Hz, 1 H, H-2), 3.78 (s, 3 H, OCH_3), 3.76 (s, 3 H, OCH_3), 2.19 (s, 3 H, Ar- CH_3), 1.48 (s, 3 H, *tert*- CH_3), 1.24 (s, 3 H, *tert*- CH_3), 0.65 (s, 3 H, *tert*- CH_3). ^{13}C NMR (75 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 214.2 (C, C=O), 170.2 (CH, C-3), 151.6 (C), 151.5 (C), 129.8 (C), 127.0 (CH, C-2), 125.8 (C), 114.6 (CH, C-6'), 111.2 (CH, C-3'), 56.0 (CH₃, OCH_3), 55.4 (CH₃, OCH_3), 54.8 (C, C-5), 50.9 (C, C-4), 25.8 (CH₃), 20.1 (CH₃), 16.2 (2 C, CH₃). MS: m/z (%) = 274 (42) [M^+], 260 (17), 259 (100), 244 (13), 229 (12), 216 (10). HRMS: m/z [$\text{M} + \text{Na}$] calcd for $\text{C}_{17}\text{H}_{22}\text{O}_3\text{Na}$: 297.1467; found: 297.1466. For the cyclopentanone **8**: IR (neat): 1735, 1505 cm^{-1} . ^1H NMR (300 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 6.78 (s, 1 H, Ar-H), 6.62 (s, 1 H, Ar-H), 3.78 (s, 3 H, OCH_3), 3.70 (s, 3 H, OCH_3), 2.65–2.30 (m, 3 H), 2.18 (s, 3 H, Ar- CH_3), 2.15–1.90 (m, 1 H), 1.37 (s, 3 H, *tert*- CH_3), 1.20 (s, 3 H, *tert*- CH_3), 0.67 (s, 3 H, *tert*- CH_3). ^{13}C NMR (75 MHz, $\text{CDCl}_3-\text{CCl}_4$): δ = 221.4 (C, C=O), 151.9 (C), 151.4 (C), 132.5 (C), 125.2 (C), 114.4 (CH, C-6'), 111.2 (CH, C-3'), 56.0 (CH₃, OCH_3), 54.8 (CH₃, OCH_3), 52.7 (C), 48.9 (C), 34.3 (CH₂), 32.7 (CH₂), 23.7 (CH₃), 21.9 (CH₃), 21.7 (CH₃), 16.0 (CH₃). MS: m/z (%) = 276 (92) [M^+], 261 (28), 227 (16), 205 (100), 192 (27), 177 (32), 175 (24), 174 (22), 149 (24), 105 (15), 91 (28). HRMS: m/z [$\text{M} + 1$] calcd for $\text{C}_{17}\text{H}_{25}\text{O}_3$: 277.1803; found: 277.1803. For enokipodin A (±)-**1**: IR (neat): 3390, 1288, 1194, 1146, 1036, 992, 943, 905 cm^{-1} . ^1H NMR (300 MHz, CDCl_3-

CCl_4): δ = 6.54 (s, 1 H, Ar-H), 6.50 (s, 1 H, Ar-H), 4.34 (s, 1 H, OH), 2.77 (s, 1 H, OH), 2.17 (s, 3 H, Ar-CH₃), 2.25–2.00 (m, 2 H), 1.87 (ddd, J = 12.3, 11.1, 6.9 Hz, 1 H), 1.76 (ddd, J = 12.3, 9.6, 3.3 Hz, 1 H), 1.23 (s, 3 H, *tert*-CH₃), 1.09 (s, 3 H, *tert*-CH₃), 0.80 (s, 3 H, *tert*-CH₃). ¹³C NMR (75 MHz, CDCl₃-CCl₄): δ = 147.5 (C), 146.1 (C), 131.1 (C), 122.4 (C), 116.9 (CH, C-5), 111.0 (CH, C-2), 109.6 (C, HO-C-O), 47.3 (C), 43.3 (C), 38.2 (CH₂), 34.8 (CH₂), 18.5 (CH₃), 16.0 (CH₃), 15.5 (2 × C, CH₃). MS: m/z (%) = 248 (37) [M⁺], 178 (9), 177 (100), 162 (32), 149 (67). HRMS: m/z calcd [M + Na] for C₁₅H₂₀O₃Na: 271.1310; found: 271.1307. For enokipodin B (±)-**2**: IR (neat): 1732, 1650, 1346, 1251, 1066, 998, 932, 842 cm⁻¹. ¹H NMR (300 MHz, CDCl₃-CCl₄): δ = 6.66 (s, 1 H, H-5), 6.55 (q, J = 1.5 Hz, 1 H, H-2), 2.55–2.20 (m, 3 H), 2.04 (d, J = 1.5 Hz, 3 H, *olefinic*-CH₃), 1.87 (ddd, J = 12.7, 8.0, 3.0 Hz, 1 H), 1.32 (s, 3 H, *tert*-CH₃), 1.22 (s, 3 H, *tert*-CH₃), 0.75 (s, 3 H, *tert*-CH₃). ¹³C NMR (75 MHz, CDCl₃-CCl₄): δ = 219.9 (C, C=O), 187.8 (C, C=O), 187.5 (C, C=O), 153.5 (C), 144.4 (C), 135.3 (CH), 134.1 (CH), 52.3 (C), 49.0 (C), 33.7 (CH₂), 31.2 (CH₂), 23.2 (CH₃), 22.3 (CH₃), 20.6 (CH₃), 15.0 (CH₃). MS: m/z (%) = 246 (3) [M⁺], 218 (20), 203 (12), 190 (47), 175 (100), 161 (21), 147 (16). HRMS: m/z [M + Na] calcd for C₁₅H₁₈O₃Na: 269.1154; found: 269.1166. For HM-1 methyl ether **17**: IR (neat): 1504, 1389, 1372, 1260, 1212, 1181, 1048, 861, 808, 704 cm⁻¹. ¹H NMR (300 MHz, CDCl₃-CCl₄): δ = 6.77 (s, 1 H, Ar-H), 6.60 (s, 1 H, Ar-H), 3.77 (s, 3 H, Ar-OCH₃), 3.73 (s, 3 H, Ar-OCH₃), 2.55–2.40 (m, 1 H), 2.17 (s, 3 H, Ar-CH₃), 1.85–1.50 (m, 5 H), 1.34 (s, 3 H, *tert*-CH₃), 1.14 (s, 3 H, *tert*-CH₃), 0.70 (s, 3 H, *tert*-CH₃). ¹³C NMR (75 MHz, CDCl₃-CCl₄): δ = 152.6 (C), 151.1 (C), 133.9 (C), 124.4 (C), 115.0 (CH, C-6'), 112.1 (CH, C-3'), 56.0 (CH₃, OCH₃), 55.5 (CH₃, OCH₃), 51.4 (C), 44.6 (C), 41.9 (CH₂), 40.0 (CH₂), 27.6 (CH₃), 26.0 (CH₃), 23.4 (CH₃), 20.8 (CH₂), 16.0 (CH₃, Ar-CH₃). MS: m/z = 262 (91) [M⁺], 248 (15), 205 (21), 192 (45), 191 (23), 179 (100), 177 (30), 165 (33), 152 (32), 149 (26).

Acknowledgement

We thank Prof. Tahara at Hokkaido University for providing the copies of the spectra of natural enokipodins A and B; and the Council of Scientific and Industrial Research for the financial support.

References

- (1) Miles, P. G.; Chang, S. T. *Mushroom Biology: Concise Basics and Current Developments*, Part III; World Scientific: Singapore, **1997**, Chap. 6, 103–117.
- (2) (a) Ishikawa, N. K.; Yamaji, K.; Tahara, S.; Fukushi, Y.; Takahashi, K. *Phytochemistry* **2000**, *54*, 777. (b) Ishikawa, N. K.; Fukushi, Y.; Yamaji, K.; Tahara, S.; Takahashi, K. *J. Nat. Prod.* **2001**, *64*, 932.
- (3) Toyota, M.; Koyama, H.; Asakawa, Y. *Phytochemistry* **1997**, *46*, 145.
- (4) Kajimoto, T.; Yamashita, M.; Imamura, Y.; Takahashi, K.; Nohara, T.; Shibata, M. *Chem. Lett.* **1989**, 527.
- (5) Asakawa, Y.; Kondo, K.; Tori, M. *Phytochemistry* **1991**, *30*, 325.
- (6) (a) Bottom, C. B.; Siehr, D. J. *Phytochemistry* **1975**, *14*, 1433. (b) Bullock, J.; Darbyshire, J. *Phytochemistry* **1976**, *15*, 2004. (c) Thomson, R. H. In *Naturally Occurring Quinones*; Academic Press: London, **1971**, 734. (d) Natori, S.; Inouye, Y.; Nishikawa, H. *Chem. Pharm. Bull.* **1967**, *15*, 380. (e) Natori, S.; Nishikawa, H.; Ogawa, H. *Chem. Pharm. Bull.* **1964**, *12*, 236.
- (7) Paul, T.; Pal, A.; Gupta, P. D.; Mukherjee, D. *Tetrahedron Lett.* **2003**, *44*, 737.
- (8) (a) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413. (b) Fürstner, A. *Angew. Chem., Int. Ed.* **2000**, *39*, 3013. (c) Trnka, T. M.; Grubbs, R. H. *Acc. Chem. Res.* **2001**, *34*, 18.
- (9) Fuganti, C.; Serra, S. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3758.
- (10) McKenzie, T. C. *Org. Prep. Proced. Int.* **1987**, 435.